NDA[removed]S-001 NDA[removed]S-001 Page 4 Baraclude®

First Page		Document Content
Date: 2009-03-31 14:46:59 Medicine Entecavir Hepatitis B Lamivudine Reverse-transcriptase inhibitor Viral hepatitis Nucleoside analogue Adefovir Antiretroviral drug Purines Chemistry Organic chemistry		NDA[removed]S-001 NDA[removed]S-001 Page 4 Baraclude® Add to Reading List Source URL: www.accessdata.fda.gov Download Document from Source Website File Size: 212,55 KB Share Document on Facebook

	JCPJCP CE Activities Log onto https://accp1.inreachce.com/ to access these activities. Clinical Response JCP - August, 2014: Positive Clinical Response to Clopidogrel is Independent of Paraoxonase I Q192R and CYP2C19 Gen DocID: 1ftMp - View Document
	Entecavir and Hepatitis B Background on Hepatitis B Hepatitis B virus (HBV) is highly endemic in South Africa and across sub-Saharan Africa, where around 8% of people are chronically infected, and rates of HBV-related li DocID: 18mXH - View Document
	The right upper quadrant Chronic hepatitis B Jennifer MacLachlan Benjamin Cowie DocID: 14aBg - View Document
	hepatitis B virus isolated on white DocID: 141Kz - View Document
	TEKMIRA PHARMACEUTICALS CORP FORM 10-K (Annual Report) DocID: 13one - View Document